Suppression of bone metastasis can improve patient quality of life. Current drugs for bone metastasis have been shown to prolong progression-free survival but not overall survival; therefore, other potential therapeutic targets for bone metastasis should be investigated. Cell-surface antigens, such as CD24, have been recently shown to be involved in the metastasis of various cancers. However, whether CD24 plays a role in bone metastasis of lung cancer remains unknown. To observe metastasis of lung cancer cells by imaging technology, we introduced a near-infrared fluorescent protein, iRFP720, into a bone-seeking subclone established from lung cancer cells, HARA-B4 cells. The anchorage-independent growth of these cells was then evaluated by colony formation assays. We also compared cancer cell tropism to bone tissue with HARA-B4 cells in the presence or absence of CD24 by cell adhesion assays.
development of such a therapeutic target. In particular, recent drug development research targeting surface antigen molecules have proven successful. 3 CD24 is a protein required for intercellular adhesion and cell differentiation, and is expressed on lymphocytes, epitheliocytes, and neuron precursor cells, where it plays an important role in neuron maturity. Recent studies have shown that CD24 is expressed in various cancer types, including pancreatic cancer, cerebral tumors, lung cancer, hepatocellular carcinoma, ovarian cancer, and breast cancer. 4 Furthermore, CD24 may play a role in the metastasis of breast cancer, [5] [6] [7] cervical cancer, 4 gastric cancer, 8 and bladder cancer, 9,10 further implicating it as a potential drug target. However, the role of CD24 in lung cancer and, in particular, its bone metastasis, remains obscure. Distant metastasis is common for lung cancer and the prognosis of such patients is usually poor, with almost no effective therapeutic method. 11 To obtain experimental in vitro and in vivo evidence for the effect of CD24 in suppressing bone metastasis progression in lung cancer, we evaluated the role of CD24 in bone metastasis of lung cancer using HARA cells, derived from human lung squamous cell carcinoma, and HARA-B4 cells, a bone-seeking subclone established from HARA.
| MATERIALS AND METHODS

| Cell culture
The human squamous lung cancer cell line HARA and its bone- FBS and 1% penicillin-streptomycin. All cell lines were maintained in an incubator at 5% CO 2 and 37°C. To induce anoikis, apoptosis due to inadequate cell adhesion, HARA and HARA-B4 cells were cultured in ultra-low attachment dishes (Corning, NY, USA) in RPMI under serum-free conditions and incubated at 37°C and 5% CO 2 for 2 weeks.
| Quantitative real-time PCR analysis
Total RNA was isolated using TRIsure (Nippon Genetics, Tokyo, Japan). cDNA was synthesized from total RNA using ReverTra Ace reverse transcriptase (Toyobo, Osaka, Japan) and oligo-dT15. Quantitative real-time PCR was carried out using primer sequences listed in Table S1 , the KAPA SYBR FAST ABI Prism qPCR Kit (Kapa Biosystems, Wilmington, MA, USA), and PicoReal96 (Thermo Fisher Scientific, Kanagawa, Japan) according to the manufacturers' instructions. Gene expression was normalized to that of the input control (GADPH).
| Plasmid, transfection, and virus transduction
The near-infrared fluorescent protein 720 (iRFP720) sequence was amplified from piRFP720-N1 (Addgene, Cambridge, MA, USA) using primer sequences listed in Table S1 . To detect cell-surface CD24 expression, flow cytometry was carried out according to standard procedures. Cells were harvested and resuspended in 2 9 10 5 /100 lL FACS buffer (1% FBS in PBS). Each cell solution (100 lL) was incubated with 5 lL anti-CD24 antibody (Miltenyi Biotec, Bergisch Gladbach, Germany) or 0.5 lL isotype control (Miltenyi Biotec) for 30 minutes at 4°C. After washing with FACS buffer, samples were analyzed using MACS Quant (Miltenyi Biotec).
The shRNA target sequences were designed using the Oligoengine workstation (DNA Engine, Seattle, WA, USA) (Table S2 ). To generate stable shRNA-CD24 cell lines, we used two different shRNAs against CD24 to control for non-specific effects. As these shRNAs were designed to target the 3 0 -UTR, the non-coding region, they were not expected to disturb CD24 overexpression. The shRNAs against luciferase or CD24 were annealed and cloned into a pSUPER-purovector (Addgene), and Xba1-Pac1 fragments were inserted into an FG12 lentiviral vector (Addgene) containing GFP as an infection marker, according to the manufacturer's instructions. The full-length cDNA for CD24 was subcloned into the retroviral vector, pMXs-IRES-Hyg, the plasmid was introduced into PlatA cells, as described above, and the supernatant was applied to shCD24 #1 and #2 cells with 10 lg/mL polybrene. On day 2 following infection, hygromycin (25 lg/mL) was added to the cultures for selection. The resulting stable cell lines were called iRFP720-HARA-B4/shCD24 + rCD24 #1 and #2. 
| Cell adhesion assay
MG-63, SAOS-2, the mouse primary osteoblasts, MC3T3E1, and NIH3T3 cells were grown to confluence and cultured as described in the "Cell culture" section. Osteoblast differentiation was assessed by measuring osteoblast differentiation markers by real-time PCR, as described previously. 13 The cell adhesion assay was undertaken as described previously. 14 
| Cell proliferation
The proliferation assay was undertaken using the Hemacolor assay kit (Merck, Darmstadt, Germany). The supernatant of cell monolayers cultured in 96-well plates was removed and the cells were quickly air dried. The monolayers were fixed with solution 1 (50 lL/well) for 30 seconds, and stained with solution 2 (80-100 lL/well) for 60 seconds followed by solution 3 (80-100 lL/well) for another 60 seconds. The plates were washed with water three times, filled with water again and left to sit for 5 minutes before the water was removed and the plates were air dried. Stain extraction was carried out using 0.5% SDS (Sigma-Aldrich) dissolved in PBS (0.2 mL/well) for 90 minutes and the change in absorbance was measured at 600
or 630 nm using a microplate reader, as described previously. 
| Histopathological examination
Areas on the spine and hind leg bones of mice with fluorescence signal were fixed in 10% neutral buffered formalin then decalcified with K-CX (FALMA, Tokyo, Japan) for approximately 24 hours before paraffin embedding and processing on regular slides. Sectioned tissue was stained with H&E and examined using an Olympus BH2 microscope with a DP20 digital camera (Olympus, Tokyo, Japan).
| Statistical analysis
Results are presented as mean AE SD. Group comparisons were carried out using the parametric Student's t-test. Differences at P < .05
were considered significant.
3 | RESULTS
| CD24 is highly expressed in bone-directional lung cancer cells
Previous studies have shown that CD24 is associated with poor prognosis of several cancers. 4, 16, 17 Consistent with this, meta-analysis data indicate that the overall survival rate of patients with high CD24 expression is lower than that for those with low CD24 expression for breast, bladder, and lung cancer (Figure 1) . However, the role of CD24 in lung cancer, in particular, its bone metastasis, remains unknown. Therefore, to examine whether CD24 plays a role in bone metastasis of lung cancer, we used HARA-B4 cells, which are a bone-seeking subclone established from HARA cells, a human lung squamous cell carcinoma cell line, as a bone metastasis model.
HARA-B4 cells show increased anchorage-independent growth, a feature of malignant cells forming tumors in vivo, which is associated with highly metastatic cancer cells. 18, 19 CD24 expression in HARA-B4 cells was significantly higher than in HARA cells (Figure 2A ). This result was consistent with microarray data (GSE29367 at NCBI Gene Expression Omnibus: https://www.ncbi.nlm.nih.gov/geo/). We subsequently cultured HARA and HARA-B4 cells for 2 weeks in low attachment dishes and examined cell viability under anchorageindependent conditions. CD24 expression was confirmed at 1, 3, and 6 days after incubation by real-time PCR. HARA-B4 cells were more viable in anchorage-independent conditions than HARA cells ( Figure 2B ). In this regard, CD24 expression was significantly higher in HARA-B4 than HARA cells ( Figure 2C ) under normal and anchorage-independent conditions. Moreover, CD24 expression was higher in HARA-B4 cells in the anchorage-independent condition than in the normal condition. These findings indicate that CD24 plays an important role in anchorage-independent growth.
| Generation of HARA-B4 cells expressing iRFP
To investigate the mechanisms underlying bone metastasis in lung cancer cells, we generated a stable cell line by introducing an expression vector containing iRFP720 into HARA-B4 cells. Expression of iRFP720
was confirmed by FACS analysis ( Figure S1A ). The iRFP720 protein can be readily detected in vivo 20 because its absorption in mammalian tissue is minimal and does not require luminescent material. Therefore, it is suitable for deep tissue whole-body imaging 21 and monitoring the kinetics and emergence of bone metastatic lesion by the IVIS spectrum. shCD24, and resistant cells was evaluated using soft agar colony formation assays. Two weeks after plating, all three cell types colonized in the soft agar medium; however, the number and size of shCD24 cell colonies were reduced compared to those of shLuc cells (Figure 3A) . The number of colonies formed by shCD24 #1 and shCD24 #2 cells were reduced by 72% and 92%, respectively ( Figure 3B ).
Inhibition of colony formation by shCD24 expression was reversed in resistant cells ( Figure 3A) , with recovery to 61% and 72% in resistant #1 and resistant #2 cells, respectively. These data suggest that CD24 is involved in the anchorage-independent growth of HARA-B4 cells. We also investigated the impact of CD24 expression on the proliferation motility of HARA-B4 cells using the Hemacolor assay.
The shLuc, shCD24, and resistant cells were seeded and cell colonies were counted after 1, 2, 3, and 4 days. There was no significant difference in the cell proliferation rate among these cell lines (Figure S2A) . Therefore, the difference in colony formation was independent of cell proliferation, suggesting that CD24 is not associated with the regulation of cell proliferation. To investigate a role for CD24 in the control of cancer cell tropism to bone, we examined whether CD24 regulates HARA-B4 adhesion to osteoblasts. This was achieved by measuring the difference in adhesion between CD24-expressing and -knockdown cells with the osteosarcoma cell 
| CD24 suppresses bone metastasis in vivo
To characterize the role of CD24 in bone metastasis of HARA-B4 cells in vivo, shLuc, shCD24, and resistant cells (2 9 10 5 cells) were inoculated into the left cardiac ventricle of male nude mice and whole body imaging was undertaken using IVIS ( Figure 4A ). Expression of iRFP720 was observed in bone from all nude mice inoculated with shLuc cells, three of five with shCD24 cells, and four of five with resistant cells ( Figure 4B ). There tended to be more bone metastases in the spine, ribs, and hind legs ( Figure 4B ), which is consistent with a previous study. 22 Although muscle metastases were also frequently noted, little metastasis was observed in other organs, consistent with a previous study. 12 The total number of metastatic sites was 46, 5, and 37 for shLuc, shCD24, and resistant cell-inoculated mice, respectively ( Table 1 ), indicating that shLuc-and resistant cell-inoculated mice showed significantly more metastases than shCD24 cell-inoculated mice ( Figure 4C , Table S3 ). Computed tomography images confirmed osteolysis in most of the individual bone metastases in the 5 weeks after injection ( Figures 4D, S4 ). Furthermore, H&E staining confirmed that infiltrating tumor cells were present in the medullary cavity in bone metastatic specimens from shLuc-and resistant cell-inoculated mice ( Figure 4E ). These results indicate that knockdown of CD24 markedly reduces bone metastasis of HARA-B4 cells in vivo.
| DISCUSSION
In this study, we showed that CD24 is highly expressed in a bone metastatic lung cancer cell line and under metastatic conditions. CD24
promotes the bone metastasis of lung cancer cells in vitro and in vivo by promoting anchorage-independent growth and adhesion. These results provide evidence for the potential of CD24 as a therapeutic candidate for the prevention of bone metastasis of lung cancer.
We used a parental cell line, HARA, prepared from a human lung cancer (lung squamous cell carcinoma) cell line, and a bone-seeking frequency of metastasis to organs other than bone. 12 As our data indicated that CD24 gene expression was significantly higher in HARA-B4 than HARA cells, and under non-anchorage-dependent conditions, and previous reports suggested a potential association between CD24 and metastasis or cancer growth, [4] [5] [6] 8, 9 we hypothesized that CD24 might play a role in bone metastasis.
This study is the first to show a role for CD24 in the bone metastasis of lung cancer cells. Although CD24 has been linked to metastatic invasion in several cancers, including breast cancer, evidence specifically for metastasis to bone has remained obscure. Our colony formation assay showed that HARA-B4 cells showed increased anchorage-independent growth, which is a feature of tumor-forming malignant cells in vivo and is associated with highly metastatic cancer cells. 18, 19 Furthermore, the anchorage-independent growth of HARA-B4 cells was reduced in shCD24 cells and was rescued by resistant cells. Consistent with previous results, the Hemacolor assay showed no differences in cell growth ability, indicating that CD24 is not involved in the regulation of cell growth. 8 In a cell adhesion assay with an osteosarcoma cell line, MG-63, shCD24 cells adhered significantly less to osteoblasts compared to normal HARA-B4 cells. This effect was reversed in CD24-resistant cells, suggesting a CD24-specific role in regulating the adhesion of lung cancer cells to osteoblasts. These findings provide evidence for a potential correlation between CD24 expression and tropism of lung cancer cells to bone tissue, which may lead to the acquisition and enhancement of bone metastatic ability. The role of CD-24 in bone metastasis was further validated in our in vivo findings; mice inoculated with F I G U R E 3 CD24 knockdown suppresses anchorage-independent growth and bone seeking. A, Anchorage-independent proliferation of HARA-B4 cells that were infected with lentivirus encoding shLuc, shRNA against CD24, or shRNA-resistant CD24. Cells were cultured for 2 wk in medium containing 19 soft agar matrix solution and examined by microscopy. Each data represents three independent experiments. B, The number of colonies formed by HARA-B4 cells was counted under microscopic inspection using ImageJ software. C, MG-63 and SAOS-2 cells were induced to undergo osteoblast differentiation. GFP-expressing cells (GFP was expressed in the shRNA vector in HARA-B4 cells) that adhered to MG-63 cells were counted under microscopic inspection (total cell count for each of four square fields for four wells). Data are shown as relative values based on that in shLuc, and are presented as the mean AE SD (n = 3). *P < .05, **P < .01
shCD24 cells showed decreased bone metastasis, which was reversed in mice inoculated with resistant cells, revealing CD24-specific effects.
Recent progress in cancer treatment has led to an increase in the incidence of bone metastases in all cancers due to the augmented survival rate of patients. The bone metastasis itself does not often become the cause of death. However, when metastasis becomes worse and comes to cause SRE, patients' activity falls and their QOL remarkably decreases. As a result, patients become bedridden, and aspiration-related pneumonia or whole body weakening have an In vivo experiments indicated that bone metastasis can be tracked using iRFP720. The iRFP720 protein is easy to handle and has much better tissue permeability than other fluorescent proteins due to its long wavelength fluorescence, and is minimally absorbed by tissue. 20 With an excitation/emission maxima at 690/713 nm, iRFP is stably expressed and emits a clear signal for detecting deep visceral lesions compared to far-red fluorescent proteins. 25 Furthermore, iRFP720 with excitation at >700 nm and emission at 810-875 nm enables it to be detected with high specificity, with reduced technical complexity and costs compared to luciferin-based bioluminescence imaging. Therefore, iRFP720 is useful for in vivo imaging analysis of bone metastasis.
CD24, a glycosyl-phosphatidylinositol-anchored sialoglycoprotein, is a membrane protein involved in intercellular adhesion and cell differentiation. We confirmed that CD24 is involved in bone metastasis of cancer cells, suggesting a possible correlation between CD24 and tropism to bone tissue of lung cancer cells. CD24 has also been linked to tumor metastasis and invasion through its function as a ligand for P-selectin and adhesion receptors in activated endothelial cells and platelets. 26 Most cancer cells can bind to platelets through CD24-mediated binding to P-selectin, which thereby promotes their escape into the bloodstream and increases their metastasis. 27 A recent study suggested that CD24 expression was critical for tumor growth and migration, 10 and CD24 expression reduces stromal cellderived factor-1-mediated cell migration and signaling through C-X-C motif chemokine receptor 4. 6 These factors might also participate in the bone metastasis mechanism by CD24, therefore, it is necessary to progress the search of molecules associated with CD24. Previous studies have also shown that overexpression of CD24 contributes to cell growth and invasion in vitro. 28 Immunohistochemical studies have linked overexpression of CD24 with pathological grade, lymph node metastasis, and subsequent clinicopathological features, such as poor prognosis of cervical, 4 bladder, 16, 17 and prostate cancers. 10 CD24 is also associated with cancer metastasis in bladder 9,10 and breast cancers. 7 Although our results suggest that CD24 plays a pivotal role in the bone metastasis of a single lung cancer cell line, future studies should verify these findings with other cell lines. Additionally, studies are required to verify whether CD24 functions directly or indirectly to promote bone metastasis using drugs that target CD24. Importantly, inhibition of CD24 by mAbs and siRNAs have been reported to reduce primary tumor growth and metastasis of colon, pancreas, and bladder cancers, 29, 30 suggesting that bone metastasis of lung cancer can be suppressed by drugs targeting CD24.
In conclusion, we have shown that CD24 is highly expressed in a bone metastatic lung cancer cell line, promotes anchorage-independent growth and adhesion in vitro, and that CD24-knockdown suppressed bone metastasis of lung cancer cells in vivo. Our results provide evidence that CD24 may be considered a promising therapeutic candidate for bone metastasis of lung cancer.
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